While median survival improvements in advanced HCC are notable, the truly revolutionary impact of immunotherapy is the creation of a long-term survival "tail" on the Kaplan-Meier curve. Clinicians now manage patients for years, a reality that was nonexistent in the pre-IO era.

In the Keynote 522 trial for early-stage TNBC, adding pembrolizumab to chemotherapy resulted in only a modest improvement in pathological complete response (pCR). Surprisingly, this small initial gain translated into much more robust and significant long-term improvements in event-free and overall survival.

The ADC mirvetuximab is the first drug to demonstrate an overall survival benefit for platinum-resistant ovarian cancer. This groundbreaking result establishes a higher efficacy standard that subsequent therapies will likely need to meet for regulatory approval and clinical adoption, raising the bar for future drug development.

Dr. Carbone argues that traditional metrics like median survival or response rate are less relevant for immunotherapies. The true measure of success is the percentage of patients alive at five or six years—the "tail of the curve"—as this indicates a durable, potentially curative, response.

CarsGen's Satracel approval in China marks a milestone, but its efficacy is modest—doubling progression-free survival from under two to under four months. Unlike long-term remissions seen with hematological CAR-Ts, this first-generation therapy represents an incremental advance, setting a different bar for success in this challenging area.

Early data for Tarlatamab in SCLC maintenance reveals an 82% 12-month overall survival. This is an absolute 30% improvement over the experimental arm of the recent MFORTE trial, signaling a potential paradigm shift in treatment outcomes that far surpasses current immunotherapy combinations.

While depth of response strongly predicts survival for an individual patient, the FDA analysis concludes it cannot yet be used as a surrogate endpoint to replace overall survival in pivotal clinical trials. It serves as a measure of drug activity, similar to response rate, but is not sufficient for drug approval on its own.

In rare NRG1-fusion positive cancers, targeted therapy shows a modest 29% objective response rate, below the typical 40% benchmark for accelerated approval. However, the median duration of response is nearly a year (and 1.5 years in naive patients), making it a highly effective, life-altering therapy for responders. This highlights duration, not just rate, as a key efficacy metric.

The LEAP-010 trial showed a combination therapy improved tumor response and progression-free survival but failed to improve overall survival, the ultimate measure of benefit. This highlights the risk of relying on surrogate endpoints, which can be misleading, especially when a treatment adds significant toxicity.